Assertio   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Newark CA United States (1995)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2006
NCT00712439
First Marketed Drug
2005
ciprofloxacin (cipro)
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ASSERTIO | DepoMed | DEPOMED INC | DEPO NF | Sponsor/Depomed, Inc.

Active Ingredients

Marketed Drugs (4)

Key: Assertio (3) Acquired (1)

ciprofloxacin (cipro) (2005)

diclofenac (voltaren) (2009)

gabapentin (neurontin) (2011)

tapentadol (nucynta) (2008)

Drugs in Phase 4 Trials (6)

Key: Assertio (3) Acquired (3)

diclofenac (voltaren) (6 trials)

fentanyl (Innovar) (4 trials)

gabapentin (neurontin) (9 trials)

ketorolac (acuvail) (12 trials)

pregabalin (lyrica) (1 trial)

propoxyphene (Darvon) (1 trial)

Drugs in Phase 3 Trials (4)

Key: Assertio (1) Acquired (3)

oxycodone (oxycontin) (3 trials)

tapentadol (nucynta) (2 trials)

tranexamic acid (cyklokapron) (1 trial)

xp20b (1 trial)

Drugs in Phase 2 Trials (5)

Key: Assertio (3) Acquired (2)

carbidopa (sinemet) (1 trial)

carvedilol (coreg) (1 trial)

dopamine (intropin) (1 trial)

levodopa (larodopa) (1 trial)

morphine (2 trials)

Drugs in Phase 1 Trials (5)

Key: Assertio (0) Acquired (5)

acetaminophen (tylenol) (1 trial)

fluticasone (cutivate) (1 trial)

hydrocodone (hycodan) (1 trial)

lidocaine (xylocaine) (1 trial)

oxymetazoline (ocuclear) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 4)

Diabetic Neuropathies (Phase 2)

Dyspnea (Phase 2)

Headache (Phase 4)

Hot Flashes (Phase 3)

Migraine Disorders (Phase 4)

Neuralgia (Phase 3)

Neuralgia, Postherpetic (Phase 3)

Pain, Postoperative (Phase 2)

Pain, Procedural (Phase 4)

Parkinson Disease (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 43
  • # of Trial APIs: 20